GNA13
GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.
Overview
Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1).
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Bladder Urothelial Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.
- 1 · What it is
GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.
- 2 · What goes wrong in cancer
Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems.
- 3 · How drugs use it
No product in this corpus aims at GNA13 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:4381 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14344 (protein name, function text, keywords and locations (REST API)); CIViC gene GNA13 (3 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Burkitt Lymphoma (GraphQL API, CC0)); IntOGen GNA13 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1). Promotes tumour cell invasion and metastasis by activating RhoA/ROCK signalling pathway. Inhibits CDH1-mediated cell adhesion in a process independent from Rho activation. In lymphoid follicles, transmits P2RY8- and S1PR2-dependent signals that lead to inhibition of germinal centre (GC) B cell growth and migration outside the GC niche. Location: Cell membrane; Melanosome; Cytoplasm; Nucleus (UniProt). Locus 17q24.1 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (DLBCLNOS)
- Burkitt lymphoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"GNA13" OR ABSTRACT:"GNA13" OR TITLE:"G protein subunit alpha 13" OR ABSTRACT:"G protein subunit alpha 13" OR TITLE:"Guanine nucleotide-binding protein subunit alpha-13" OR ABSTRACT:"Guanine nucleotide-binding protein subunit alpha-13" OR TITLE:"G13" OR ABSTRACT:"G13" OR TITLE:"MGC46138" OR ABSTRACT:"MGC46138") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GNA13, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSIN3A
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetID3
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetBCL7A
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetGNAI2
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, IntOGen.
- TargetTFAP4
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, IntOGen.
- TargetP2RY8
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TrialSepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma.
- TargetCCND3
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.